Skip to content

Echocardiographic Evaluation of the Effects of Levosimendan in the Treatment of Septic Cardiomyopathy

Echocardiographic Evaluation of the Effects of Levosimendan on the Treatment of Septic Cardiomyopathy

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103953
Enrollment
Unknown
Registered
2025-06-09
Start date
2022-04-02
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Cardiomyopathy

Interventions

experimental group:which received levosimendan in addition to conventional treatment
control group :received conventional treatment

Sponsors

Linyi People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
39 Years to 78 Years

Inclusion criteria

Inclusion criteria: The diagnosis of sepsis conforms to the definition and diagnostic criteria of sepsis 3.0. Currently, there is no unified diagnostic standard for septic cardiomyopathy. Based on three internationally recognized characteristics of ultrasound: (1) left ventricular dilation exists at normal or below normal filling pressure; (2) LVEF decline; (3) low volume responsiveness due to right ventricular or left ventricular systolic or diastolic dysfunction. Meeting at least one of these is used as the diagnostic reference for this study.

Exclusion criteria

Exclusion criteria: (1) Death or voluntary discharge within 72 hours after admission; (2) Patients whose ultrasound images could not be obtained; (3) Severe arrhythmias other than atrial fibrillation; (4) Patients with incomplete baseline data or those lost to follow-up.

Design outcomes

Primary

MeasureTime frame
left ventricular ejection fractions;cardiac index;

Secondary

MeasureTime frame
left ventricular ejection fractions;velocity-time integral,VTI;

Countries

China

Contacts

Public ContactHu Zhenzhen

Lin Yi People’s Hospital,Shandong Second Medical University

huzhenzhen-ice@163.com+86 159 5398 6131

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026